Re: Zenith Capital Corp. to Present on the Emerging Growth Conference on September 25, 2024
posted on
Oct 08, 2024 01:00PM
Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials
Nextblockbuster
We are in the same boat. Take it for what it's worth - promises, promises, promises.